Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia.
Sickle cell anemia is an inherited disorder of hemoglobin that leads to a variety of acute and chronic complications. Abnormal cellular adhesion, mediated in part by selectins, has been implicated in the pathophysiology of the vaso-occlusion seen in sickle cell anemia, and selectin inhibition was ab...
Main Authors: | Ted Wun, Lori Styles, Laura DeCastro, Marilyn J Telen, Frans Kuypers, Anthony Cheung, William Kramer, Henry Flanner, Seungshin Rhee, John L Magnani, Helen Thackray |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4079300?pdf=render |
Similar Items
-
Correction: Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia
by: The Staff
Published: (2014-01-01) -
Correction: Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia.
Published: (2014-01-01) -
Use of GMI‐1271, an E‐selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis
by: Sumana Devata, et al.
Published: (2020-02-01) -
Biomarkers and recent advances in the management and therapy of sickle cell disease [version 1; referees: 2 approved]
by: Marilyn J. Telen
Published: (2015-10-01) -
Optimization of magnetic properties and GMI effect of Thin Co-rich Microwires for GMI Microsensors
by: Lorena Gonzalez-Legarreta, et al.
Published: (2020-03-01)